Want to see NGEN full AI Analyst Report?
NervGen Pharma (NGEN) Income Statement
NervGen Pharma Income Statement
Last quarter (Q2 2026), NervGen Pharma's total revenue was $0.00. In Q2, NervGen Pharma's net income was $-29.99M. See NervGen Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ -83.74K | $ -145.01K | $ -114.10K | $ -42.95K | |
| $ 25.08M | $ 24.83M | $ 17.63M | $ 22.71M | $ 12.87M | |
| Depreciation and Amortization | $ 55.80K | $ 83.74K | $ 145.01K | $ 114.10K | $ 42.95K |
| $ -5.65M | $ -23.91M | $ -22.24M | $ -19.92M | $ -12.78M | |
| $ -25.08M | $ -24.92M | $ -17.78M | $ -22.82M | $ -12.91M | |
| $ -19.04M | $ 925.48K | ― | $ 2.28M | $ 85.29K | |
| $ -44.12M | $ -23.99M | $ -22.38M | $ -20.54M | $ -12.82M | |
| $ -44.12M | $ -23.99M | $ -22.38M | $ -20.54M | $ -12.82M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.61 | $ -0.36 | $ -0.37 | $ -0.39 | $ -0.33 |
| Diluted EPS | $ -0.61 | $ -0.36 | $ -0.37 | $ -0.39 | $ -0.33 |
| Weighted Average Shares Outstanding | 72.33M | 67.32M | 59.29M | 52.65M | 39.29M |
| Weighted Average Shares Outstanding (Diluted) | 72.33M | 67.32M | 59.29M | 52.65M | 39.29M |
Currency in CAD